Drug Shortage Report for TEVETEN PLUS
| Report ID | 120414 |
| Drug Identification Number | 02253631 |
| Brand name | TEVETEN PLUS |
| Common or Proper name | TEVETEN PLUS |
| Company Name | BGP PHARMA ULC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | EPROSARTAN HYDROCHLOROTHIAZIDE |
| Strength(s) | 600MG 12.5MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 2x14 |
| ATC code | C09DA |
| ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | 2020-09-23 |
| Actual start date | |
| Estimated end date | Unknown |
| Actual end date | 2020-08-04 |
| Shortage status | Avoided shortage |
| Updated date | 2020-08-04 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2020-08-04 | French | Compare |
| v3 | 2020-08-04 | English | Compare |
| v2 | 2020-07-16 | French | Compare |
| v1 | 2020-07-16 | English | Compare |
Showing 1 to 4 of 4